Score Your Stock

US stock · figures in US dollars · scored on full-year results

Align Technology Align Technology, Inc.

ALGN · Healthcare · Medical Instruments & Supplies
Bottom 38% of scored stocks
OkayBottom 38% of scored stocks
Weak Spot

Align Technology scores 48/100 on fundamentals: in the bottom 38% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (75/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 75
Weakest
Price 0
  • Carries a Weak Spot flag

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 10.5b#491 of 503 in the S&P 500EPSUS$ 6.86P/E21.7×✓ vs sector median 30.5×P/B2.5×✓ vs sector median 4×Div yieldNo dividends paidBottom 19% in the S&P 50052w range · 26% of range130.23200.44
as of 31 Oct 2026

Nearby peers

Ranks #40 of 60 in Healthcare by score

#1Universal Health Services79#38Pfizer50#39Vertex Pharmaceuticals50
#40Align Technology48
#41Illumina48#42Johnson & Johnson48

One-Minute Summary

Why Align Technology scores 48

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

40
Why 40?
Pillar score: (1 + 1 + 1 + 1 + 0) = 4 of 10 points → 40
Return on Equity (ROE)12%Okay4-Year Revenue Growth+2%/yrOkay4-Year Profit Growth+3%/yrOkayNet Profit Margin12%OkayQuarterly Momentum+4%Weak
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +10.5%Equity ↑ +16.6%ROE % 11.6%
Net ProfitEquityROE %
445m421m410m492m3.6b3.9b4.0b4.2b202320242025TTM12.3%10.9%10.1%11.6%

Revenue & Net Profit, with Net Margin

Revenue ↑ +7.7%Net Profit ↑ +10.5%Net Margin % 11.8%
RevenueNet ProfitNet Margin %
3.9b4.0b4.0b4.2b445m421m410m492m202320242025TTM11.5%10.5%10.2%11.8%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

Profit climbed about 10.5% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +8%Net Profit ↓ -6.6%Net Margin % 10.3%
RevenueNet ProfitNet Margin %
978m995m979m1.0b996m1.0b1.0b1.1b116m103m93m125m57m136m113m108mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2611.9%10.4%9.5%12.3%5.7%13%10.8%10.3%
▬▼▼▲▼▲▲▼

Sales grew about 8% over the last 8 quarters: customers keep spending more with this company.

Profit has moved sideways over the last 8 quarters.

Why 75?
Pillar score: (2 + 1) = 3 of 4 points → 75 · 1 N/A skipped
Debt-to-Equity0×StrongCurrent Ratio1.4×Okay

No data: Interest Coverage

Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -4.6%Equity ↑ +16.6%D/E 0×
Total DebtEquityD/E
127m119m114m121m3.6b3.9b4.0b4.2b202320242025TTM0×0×0×0×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +8.8%Current Liabilities ↓ -7.6%Current Ratio 1.4×
Current AssetsCurrent LiabilitiesCurrent Ratio
2.4b2.5b2.6b2.7b2.1b2.0b1.9b1.9b202320242025TTM1.2×1.2×1.4×1.4×
Why 63?
Pillar score: (0 + 1 + 2 + 2) = 5 of 8 points → 63
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive but bumpyOkayFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↓ -4.6%Free CF ↑ +3.2%
Operating CFFree CF
786m738m593m750m608m623m491m628m202320242025TTM

Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.

Cash vs Total Debt

Cash ↑ +17.6%Short-Term Debt ↑ +15.2%Total Debt ↓ -4.6%
CashShort-Term DebtTotal Debt
937m1.0b1.1b1.1b30m31m32m34m127m119m114m121m202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio21.7×WeakP/B Ratio2.5×WeakPEG Ratio6.4Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 190.10US$ 162.47US$ 134.84Oct '25Feb '26Jun '26Oct '26

The share price is up about 8.7% over the past year.

Why 67?
Pillar score: (1 + 1 + 2 + 2 + 1 + 1) = 8 of 12 points → 67
Earnings ConsistencyUnevenOkayDebt Trend (4yr)StableOkayShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)-13.1 pp/yr vs salesStrongAsset Turnover Trend (4yr)+2.1%OkayQuarterly Consistency2 of 4 quarters downOkay
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +7.7%Inventory ↓ -28.5%Inv. % of Rev. 5.1%
RevenueInventoryInv. % of Rev.
3.9b4.0b4.0b4.2b297m254m226m212m202320242025TTM7.7%6.4%5.6%5.1%
Ranks #40 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#38Pfizer50#39Vertex Pharmaceuticals50
#40Align Technology (you)48
#41Illumina48#42Johnson & Johnson48

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 4.2bUS$ 491.9mUS$ 749.9mUS$ 627.8mUS$ -122.1mUS$ 1.1bUS$ 120.8mUS$ 34.2mUS$ 4.2bUS$ 2.7bUS$ 1.9bUS$ 6.4bUS$ 2.2bUS$ 212.2m-12%12%0.0×1.4×----
2025US$ 4.0bUS$ 410.4mUS$ 593.2mUS$ 490.8mUS$ -102.4mUS$ 1.1bUS$ 114.4mUS$ 31.9mUS$ 4.0bUS$ 2.6bUS$ 1.9bUS$ 6.2bUS$ 2.2bUS$ 226.3mUS$ 0.0m10%10%0.0×1.4×0%27.1×2.8×6.3
2024US$ 4.0bUS$ 421.4mUS$ 738.2mUS$ 622.7mUS$ -115.6mUS$ 1.0bUS$ 119.3mUS$ 31.1mUS$ 3.9bUS$ 2.5bUS$ 2.0bUS$ 6.2bUS$ 2.4bUS$ 254.3mUS$ 0.0m11%11%0.0×1.2×0%36.5×4.0×4.6
2023US$ 3.9bUS$ 445.1mUS$ 785.8mUS$ 608.1mUS$ -177.7mUS$ 937.4mUS$ 126.6mUS$ 29.7mUS$ 3.6bUS$ 2.4bUS$ 2.1bUS$ 6.1bUS$ 2.5bUS$ 296.9mUS$ 0.0m12%12%0.0×1.2×0%46.2×5.7×2.0